Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation CELG today announced that results from a
retrospective analysis of patients with International Prognostic Scoring
System (IPSS) Low- or Intermediate (Int)-1-risk myelodysplastic
syndromes (MDS) with del(5q) treated with REVLIMID® (lenalidomide) were
presented at the American Society of Hematology annual meeting in New
Orleans, La.
In the analysis, 286 patients from the MDS-003 and MDS-004 studies
received lenalidomide from the study start. Of the total, 181 were
evaluable for both cytogenic response (CyR) and red-blood cell
transfusion independence (RBC-TI) of at least 26 weeks, (88 patients
from MDS-003 and 93 patients from MDS-004).
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in